((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
November 6 – **Shares of cancer screening test maker Exact Sciences EXAS.O fell 24.9% to $53.72
** After market close Tuesday, the company lowered its total revenue and screening revenue forecasts for 2024
**The company now projects revenue between $2.73 billion and $2.75 billion, up from a previous estimate of $2.81 billion to $2.85 billion
**Hurricanes are the main reason revenue declined between the third and fourth quarters CFO Aaron Bloomer said during the earnings conference call with analysts
**Disruptions caused by Hurricanes Helene and Milton negatively impacted Cologuard's orders and results in September and October. Historically, approximately 18% of Cologuard tests are performed by patients who live in affected areas,” Bloomer added.
**Cologuard is the company's flagship product that provides an at-home colon cancer screening test
**The company now expects its 2024 screening revenue guidance to be between $2.08 billion and $2.10 billion, compared to its prior guidance of $2.16 billion to $2.18 billion
**At least 7 brokerages cut forecasts on the stock after the results
**Including the session's movements, the stock is down ~10.6% year to date
